Instrument Inactif

Autres langues Medical Prognosis Institute A/S Nasdaq Copenhagen

Actions

MPIT

DK0060732477

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Allarity Therapeutics Reports First Quarter Financial Results and Highlights, including Clear Clinical Benefits from Phase 2 Trial, NASDAQ Compliance, and Significant Improvement in Cash and Equity Balances	14/05
Allarity Therapeutics Announces that All Series A Preferred and All Variable Priced Warrants have Converted to Common Stock	07/05
Allarity Therapeutics Says Stockholders' Equity 'Significantly' Exceeds Nasdaq's $2.5 Million Minimum Rule	06/05
Allarity Therapeutics Exceeds Nasdaq’s Minimum Equity Requirement; Requests Voluntarily Withdrawal of Form S-1	06/05
Wall Street Set to Open Higher Thursday After Fed Holds Rate Steady, Jobless Claims Lower Than Expected	02/05
Allarity Therapeutics’ Stenoparib Shows Clear Clinical Benefit and Achieves Significant Milestone with Early Conclusion of Phase 2 Trial in Advanced Ovarian Cancer	02/05
Allarity Therapeutics, Inc. Announces Early Discontinuation of Its Phase 2 Clinical Trial of Stenoparib	02/05
Allarity Therapeutics Regains Compliance with NASDAQ Minimum Bid Price Requirement	29/04
Allarity Therapeutics Receives NASDAQ-Approved Extension to Regain Compliance with Nasdaq Listing Rule 5550(b)(1)	17/04
Top Premarket Gainers	15/04
Top Premarket Gainers	12/04
Allarity Therapeutics to Implement 1-for-20 Reverse Stock Split	04/04
Allarity Therapeutics Announces 1-for-20 Reverse Stock Split	04/04
Allarity Therapeutics Makes Strategic Pivot to Focus Solely on Accelerating Stenoparib Toward Regulatory Approval in Advanced Recurrent Ovarian Cancer	27/03
Allarity Therapeutics Makes Strategic Pivot to Focus Solely on Accelerating Stenoparib Toward Regulatory Approval in Advanced Recurrent Ovarian Cancer	27/03
Allarity Therapeutics Receives Extension from Nasdaq Hearings Panel to Regain Compliance with Listing Rules 5550(a)(2) and 5550(b)(1)	25/03
Allarity Therapeutics : Material Agreement - Form 8-K	20/03
Allarity Therapeutics, Inc. announced that it has received $0.6 million in funding	14/03
Allarity Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	08/03
Allarity Therapeutics Reports Full Year 2023 Financial Results and Provides a Business Update	08/03

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Medical Prognosis Institute A/S Nasdaq Copenhagen

Actions

MPIT

DK0060732477

Autres langues

Filtres